RDHL
RedHill Biopharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$0.40
−3.65%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.40
From 52W high−71.38%
Volume37262.00
Market cap$3.56M
P/E (TTM)—
P/S (TTM)12.5x
Div yield—
Key dataNov 4, 2026
Open
$0.40
From 52W high
−71.38%
Volume
37262.00
Market cap
$3.56M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
38.8
MomentumView details →
1D Return
−3.65%
YTD Return
−61.16%
SummaryUpdated Jun 1, 2026
RedHill Biopharma Ltd. (NASDAQ:RDHL) is a specialty biopharmaceutical company founded in 2009 and headquartered in Tel Aviv, Israel. The company went public in 2013 and focuses primarily on developing and commercializing treatments for gastrointestinal and infectious diseases. RedHill operates as a clinical-stage biopharmaceutical company with a portfolio of marketed products and an extensive pipeline of investigational drugs in various stages of development.
Similar companies
Latest newsMore news →
RedHill Biopharma reported that in vitro studies by two microbiology centers confirmed RHB-204's ability to kill Mycobacterium avium subspecies paratuberculosis and its comparability to RHB-104 in intracellular culture and spot and phage assays.2d agoRedHill Biopharma Ltd. received a $2.9 million National Cancer Institute grant to support clinical development of opaganib combined with CAR T-cell therapy for ultra-high-risk multiple myeloma.16d ago